A method of treating hematologic malignancies associated with a high number ofcirculating tumor cells by the administration of a therapeutic chimeric anti-CD20 antibody. These malignancies include in particular B-prolymphocyticleukemia (B-PLL), chronic lymphocytic leukemia (CLL), and transformed non-Hodgkin's lymphoma.
展开▼